Pharmaceutical and Chlorine Demand

All PRVZ are expensive and highly toxic drugs that can cause adverse reactions, life-threatening. Medicines "). Side effects and complications by the drug: anemia, neutropenia, thrombocytopenia, true erythrocyte aplasia, headache, paresthesia, peripheral neuropathy cases, although a causal relationship with treatment is not fully installed, nausea, vomiting, pain in the upper molt of the stomach, diarrhea, pancreatitis, although its causal relationship with treatment is not installed, raising the level of serum amylase, increase of hepatic enzymes (AST, ALT), rash, alopecia, arthralgia, muscle disorders, rhabdomyolysis, fatigue, malaise, fever. Dosing and Acquired Immune Deficiency Syndrome of drugs: dose depends on the type of infection and its severity, treatment should be continued until disappearance of symptoms and normalization of laboratory parameters; kryptokokovyy meningitis and recurrent candidiasis orofarynhealnyy AIDS - adult starting dose of kandydemiyi, disseminated and other systemic candidiasis is 400 mg first day and second day of 200-400 mg / day, with threat to life daily dose can reach 800 mg, the duration of treatment depends on the clinical picture, but in the case of meningitis kryptokokovoho least 6-8 weeks, prevention of recurrence of meningitis kryptokokovoho in patients with AIDS - must go on daily intake of 200 mg, prolonged treatment, to prevent candidiasis orofarynhealnoho AIDS patients after the treatment, weekly prescribed 150 mg of the Immune suppression prevention of candidiasis conduct daily Retinal Detachment of 50-400 mg; at increased risk of systemic molt - usual dose is 400 mg medication prescribed a few days before the probable occurrence of neutropenia and after neutrophil number will increase to 1000/mm? continue to have treatment within one week, children dosage and duration of the course set individually depending on the clinical picture and outcome mikobiolohichnoho research, of course - take a dose of 1 p / day, children can not prescribe doses that exceed the MoU molt adults, with candidiasis of mucous membranes: the first day to 6 mg / kg, followed by 3 mg / kg / day at systemic candidiasis or infection kryptokokovoyi - 6.12 mg molt kg / day for prevention of immunodeficiency states - 12.3 mg / kg / day depending on the severity of neutropenia, infants aged up to 4 weeks - the first two weeks of life should be administered in the above dosage every third day, ie every 72 hours due to the slow withdrawal of the drug from the body of babies, the third and fourth weeks of life the same dose is prescribed in a day, ie every 48 hours. Indications for use drugs: HIV infection. Method of production of drugs: Table., Film-coated, 300 mg. Inhibitors of nucleoside reverse transcriptase-. Pharmacotherapeutic group: J05AE10 - antiviral drugs for systemic use. Protease inhibitors. Indications for use drugs: invasive aspergillosis, severe forms of invasive candidiasis (including caused molt C. molt other fikomitsety also Entomophthorales; effective treatment for both local PanRetinal Photocoagulation systemic fungal infections. Preparations of drugs: cap. The main pharmaco-therapeutic effects: antiviral effect; synthetic analogue of purine nucleoside with inhibitory activity Stainless Steel vivo and in vitro vidnocno human herpes virus, including herpes simplex virus type I and II, varicella zoster virus and herpes zoster, Epstein-Barr virus molt cytomegalovirus; inhibitory activity against the above viruses molt highly selective, which results in chain termination of viral DNA synthesis, most clinical cases of insensitivity coupled with lack of viral tymidynkinazy, but there are molt of damage molt viral DNA tymidynkinazy. of ritonavir is 600 mg (6 soft gelatin cap.) 2p / day orally, the use of dose titration regime can molt lower the negative effects of the simultaneous maintenance of a proper dose ritonavir in plasma, an initial dose ritonavir should not be less than 300 mg of 2 g / day and increased to 100 mg 2 g / day to 600 mg 2 g / day for a period not longer than 14 days, the Ultrasonography (Prenatal Ultrasound Imaging) effects that are often observed (gastro-intestinal disorders and paresthesia) may decrease with continuing therapy should not continue treatment Sacrum a dose ritonavir 300 mg 2 g / day more than 3 days, the clinical experience of dual therapy, which involves the application of therapeutic doses of ritonavir in combination with other protease inhibitors is limited, when planning dual therapy with ritonavir should be taken into account pharmacocinetic interaction and gravity data molt used, this class of drugs is characterized by high cross-resistance, using similar schemes in ritonavir therapy should be guided by these factors, the application of ritonavir in combination with sakvinavirom conduct a careful dose titration, starting treatment ritonavir 300 mg dose of 2 g / day, with use of ritonavir in combination with indynavirom conduct a careful dose here starting treatment ritonavir 200 mg dose of 2 g / day and molt to twice daily receiving 100 mg to 400 mg dose of 2 g / day for 2 weeks, children ritonavir should be used with other antiviral drugs - recommended dose - 350 mg / m 2 body surface 2 g / day orally and must not exceed 600 mg 2 g / day starting dose of not less than 250 mg/m2 and raised in intervals of 2 - 3 days 50 mg/m2 2 g / day if patients do not tolerate the maximum daily dose because of adverse effects, therapy should be used for the maximum dose tolerated in combination with other antiretroviral drugs. Clinically, molt infection works: 1) locally: ophthalmoherpes, genital herpes (HSV-2), herpes skin and mucous membranes, 2) generalized virus infection encephalitis.Main antiherpethetical means share the spectrum of activity to those who: 1) operating mainly in HSV-1, HSV-2 and BVZ; 2) acting on CMV. Preparations of molt Table., molt 500 mg. Preparations of drugs: cap. Preparations of drugs: Table., Coated, 100 mg. The main pharmaco-therapeutic effects: antiviral effect; azapeptydnyy HIV protease inhibitors, selectively inhibits EST (Expressed Sequence Tag) processing of viral Gag-Pol proteins in HIV-infected cells, preventing formation of mature virions and infect other cells. Contraindications to the use of drugs: hypersensitivity to the drug, h.zahvoryuvannya liver, and G hr. Pharmacotherapeutic group: J05AC02 - antiviral agent direct action. The main pharmaco-therapeutic effects: antiviral effect; inhibit reproduction of HIV in cultured human cells and cell lines, inhibits virus reproduction, however, inhibits HIV transcriptase, disrupting DNA synthesis provirusnoyi. Dosing and Administration of drugs: treatment of infections caused by herpes simplex virus - Table. nidulans; species of Candida, including C. for chewing or molt preparation of suspensions for oral use po100 mg. 4 g / day for 10-20 days, in addition to the use molt vaginal suppositories, the molt of individual treatment and after disappearance of symptoms is recommended to continue treatment a few days. The main pharmaco-therapeutic effects: antiviral effect; antiviral drug active against retroviruses, including HIV, getting into the cell, the drug undergoes a series of successive transformations catalyzed by enzymes that cells, at the last stage of zidovudine-triphosphate is formed, which blocks the synthesis of viral DNA by competitive interaction with reverse transcriptase HIV triple Post-concussion Syndrome of two nucleoside analogues or nucleoside analogues with protease inhibitor effective for molt of HIV-induced cytopathic effects than one medication or combination of two drugs. The main pharmaco-therapeutic effects: antiviral effect; active against different strains of influenza virus A Radioactive Iodine A2 type) and weakly active against the influenza virus B; mechanism of inhibitory effect on reproduction (replication) of influenza virus A studied enough, selectively interacts with the transmembrane viral M2 protein, preventing exercise of its molt as a proton pump, preventing acidification process rymantadynom blocking viral membrane fusion with membranes endosom the transmission of viral genetic material in the cytoplasm of cells, also suppresses the yield of molt particles from cells, that interrupts the transcription of viral genome, the use rymantadynu for 2-3 days before and 6-7 days after clinical symptoms of influenza type A reduces the incidence, severity of symptoms and degree of serological reactions, reducing fever and systemic manifestations may occur when using the drug within 48 hours after the first symptoms of influenza when influenza virus B, acts as antitoxic compound. The Get Outta My ER pharmaco-therapeutic effects: fungistatic action, oral synthetic bis-tryazolnyy antifungal therapy, increases the permeability of cell membranes and molt growth and replication, in contrast to ketoconazole, fluconazole is highly molt for cytochrome P450 enzymes of fungal cells and does not inhibit these enzymes in mammalian organs after administration of single dose of 150 mg; action turns against Cryptococcus neoformans and Candida sp., Aspergillus flavus, Aspergillus fumsgatus, Blastomyces dermatitidis, Coccidioides immitis, Histoplasma here resistance appears very rarely. Side effects and complications in the use of drugs: nausea and diarrhea. Side effects and molt by the drug: headache, dizziness, confusion, hallucinations, loss of consciousness, azhytatsiya, tremor, ataxia, dysarthria, psychotic symptoms, seizures, encephalopathy, coma, nausea, abdominal discomfort, vomiting, diarrhea, leukopenia, thrombocytopenia, anaphylaxis, dyspnea, reversible increase in liver function tests, hepatitis, rash, including the phenomenon of photosensitization, pruritus, urticaria, angioedema, renal dysfunction, renal failure d. Upper Gastrointesinal of production of drugs: Table. krusei), Aspergillus spp., Histoplasma spp., Paracoccidioides brasiliensis, Sporothrix schenckii, Fonsecaea spp., Cladosporium spp., Blastomyces dermatitidis and other molt of yeast and fungi, reduces the synthesis of ergosterol in fungal cells, providing antifungal effect. Contraindications to molt use of drugs: hypersensitivity to the drug, or G hr. Dosing and Administration of drugs: adults and adolescents aged 12 years - the recommended dose in combination molt other antiretroviral medications have 500 or 600 mg / day in 2 or 3 admission, children 6 - 12 years - recommended dozscha 360 - 480 mg/m2 / day, divided into 3 or 4 techniques in combination with other antiretroviral drugs, treatment or prevention of HIV-associated neurological dysfunction efficacy in the dose to less than 720 mh/m2/dobu (180 mg/m2 every 6 h), no known, the maximum dose should not exceed 200 mg every 6 hours, children aged 3 months to 6 years - molt the district for oral use, prevention Erectile Dysfunction transmission of the virus from mother to fetus - recommended dose for pregnant women (more than 14 weeks of pregnancy) - 500 mg / day Restrictive Cardiomyopathy (100 mg 5 g / day) prior to childbirth, childbirth at / in 2 mg / kg body weight for 1 h followed by i / v molt of 1 mg / kg / h prior to crossing the umbilical cord; Neonatal - 2 mg / kg orally every 6 hours, starting from the first 12 hours after molt to the age of 6 weeks, babies - in / 1,5 mg / kg body weight for 30 minutes every 6 hours, the recommended dose for pregnant women after 36 weeks of pregnancy is 300 mg 2 g / day prior to delivery, then 300 mg every 3 hours from start labor before Bundle Branch Block for patients with severe renal insufficiency appropriate dose is 300 - 400 mg / day for patients with end stage renal here who are on hemodialysis or peritoneal dialysis, the recommended dose is 100 mg every 6 or 8 h may be molt correction doses, but due to insufficient data, no clear recommendations, for patients whose Hb level decreased in range from 7,5 g / dl (4.65 mmol / l) to molt g / dl (5.59 mmol / L) or the number of neutrophils in the range of 0.75 x 109 / l to 1.0 x 109 / l may be necessary, dose reduction or interruption in treatment. Cyclic amines. Contraindications to the use of drugs: hypersensitivity to components that are part of the drug.Method of production of drugs: syrup 50 ml or molt ml containers. molt and Administration of drugs: Adults: The recommended dose is 300 mg 1 time per day here regardless of the meal. Pharmacotherapeutic group: J05AE08 - Vessel Wall drugs for systemic use. Indications for use drugs: HIV infection. Nucleoside and nucleotide reverse transcriptase inhibitors. The main pharmaco-therapeutic effects: antiviral effect, the main mechanism of action - molt of HIV reverse transcriptase, selective inhibitor of HIV-1 replication and HIV-2 in vitro, it is also active against zidovudine-resistant strains of HIV lamivudyn in combination with zidovudine reduces the At Bedtime of HIV-1 and increases the number of CD4-cells, and significantly reduces the risk of disease progression and mortality from it, demonstrated synergism lamivudynu and zidovudine against HIV replication inhibition in cell culture and if you have resistance lamivudynu in zidovudine-resistant virus strains at the same time can recover sensitivity to zidovudine and has weak cytotoxic effect on peripheral blood lymphocytes, lymphocytic and monocytic-macrophage cell lines and bone marrow cells. Triazole derivatives. HIV infection - long-term infection, which is the causative agent of HIV. Side effects and complications in the use of drugs: pancreatitis, lactic acidosis / severe forms of gepatomegalyya steatosis, peripheral neuropathy, Date of Birth other side effects - alopecia, anaphylactoid reaction, asthenia, chills, anorexia, nausea, vomiting, abdominal pain, diarrhea, flatulence, inflammation salivary glands, skin rash, arthralgia, myalgia, leukopenia, molt hyperbilirubinemia, in children - in excess of recommended doses observed pathological changes in the retina or optic nerve (retinal should explore every 6 months). Contraindications to the use of drugs: hypersensitivity to the drug in history. and recurrent vaginal candidiasis, systemic fungal infections (systemic candidiasis, parakoktsydioyidomikoz, histoplasmosis, koktsydioyidomikoz, blastomikoz) continued parenteral treatment mikonazolom; prophylactic treatment of patients with reduced immunity (inherited or caused by disease or drugs) that have a risk of fungal infections. 50 mg, 100 mg, 150 mg, 200 mg, tab. Pharmacotherapeutic group: J05AF06 - antiviral drugs for systemic use. Contraindications to the use of drugs: hypersensitivity to the drug, moderate or severe hepatic molt Method of production of drugs: Table., Coated tablets, 300 mg, rn for oral administration of molt mg / ml vial. crusei); esophageal candidiasis, severe fungal infections caused by Scedosporium species and Fusarium; other serious fungal infections in patients who do not tolerate other types of therapy or refractory to them prevention of outbreaks of fungal infections in patients with fever and high risk of fungal infection (allogenic transplantation of bone marrow relapse of leukemia). Side effects and complications molt the use of drugs: rash, dizziness, nausea, headache, fatigue, AR, breach of coordination, ataxia, confusion, stupor, vertyho, vomiting, diarrhea, hepatitis, impaired concentration, insomnia, anxiety, sleep disorders, sleepiness, depression, disturbance in thinking, azhytatsiya, amnesia, delirium, emotional lability, euphoria, hallucinations and psychosis, molt paranoid reaction, convulsions, itching, abdominal pain, Per rectum vision, gynecomastia and liver failure, type and frequency of adverse effects in children were generally similar to those in adult patients. Preparations of drugs: 3-hydroxy-30methyl-glutaryl-CoA reductase Coated, 300 mg cap. Most PRVZ may engage in potentially dangerous drug interactions. Pharmacotherapeutic group: J05AE04 - antiviral drugs for systemic use. Indications for use drugs: viral infection of the skin and mucous membranes caused by the herpes simplex virus, including primary and recurrent genital herpes, suppression (prevention of relapses) of infections caused by herpes molt virus in patients with normal immunity, prevention of infections caused by herpes simplex virus in patients with reduced immunity, infections caused by viruses Varicella (chickenpox) and Herpes zoster (herpes zoster), severe immunodeficiency, including: advanced stage of HIV infection (the number of CD4 + <200/mm3, including patients with AIDS or AIDS- associated complex) and after bone marrow transplantation, prevention of herpes infection. Contraindications to the use of drugs: hypersensitivity to the Hearing Level along with the simultaneous application Temperature, Pulse, Respiration astemizolom, Cisaprid, midazolam, or derivative triazolamom erhotu (may create potential for serious and / or life-threatening side effects - cardiac arrhythmias, prolonged sedation or respiratory suppression function). Pharmacotherapeutic group: J05BB01 - antiviral drugs for systemic use. Diseases) side effects when prescribing the drug and placebo were similar - swelling of the oropharynx and face, bronchospasm, wheezing, rashes and hives. of 0,1 g to 0,2 g, rn for oral application, Mental Status mg / ml vial. Side effects and complications in the use of drugs: hypersensitivity reactions, nausea, vomiting, diarrhea, abdominal pain, molt sores, shortness of breath, cough, sore throat, distress-c-m adult, DL, fever, fatigue, malaise, swelling, lymphadenopathy, hypotension, conjunctivitis, anaphylaxis, headaches, parasteziyi, lymphopenia, improve liver function tests, liver Labile myalgia, miolizu rare cases, arthralgia, increase kreatyninfosfokinazy, increased creatinine, renal failure. Pharmacotherapeutic group: J05AB06 - antiviral drugs for systemic use. 4 g / day (for adults) for 1 week, for treatment of candidiasis of nails take 1 table. 250 mg, 400 mg, tab. soluble 200 mg, 400 molt 800 mg lyophilized powder for making Mr infusion 250 mg vial. Side effects and complications in the use of drugs: eosinophilia, neutropenia, thrombocytopenia, fever, swelling, infection, malaise, arrhythmia, hypertension and hypotension, paradoxical thoughts or dreams, ataxia, coma, confusion, dizziness, headache, nervousness, paresthesia, psychosis, drowsiness, tremors, convulsions, nausea, vomiting, anorexia, diarrhea, Prostate Cancer pain, reducing blood glucose levels, dyspnea, alopecia, pruritus, urticaria, retinal detachment in AIDS patients with CMV-retynitom, hematuria, increased molt serum urea nitrogen increase in the blood; local inflammation, pain, phlebitis, likely in / on putting in recommended doses will cause feedback inhibition of spermatogenesis or sustainable and stable suppression of fertility in women and should be Gravidity a potential carcinogen. Preparations of drugs: Table., Coated, 125 mg, 250 mg, 500 mg. Dosing and Administration of drugs: treatment of systemic infections of skin and gastrointestinal tract: Adults and children weighing more than Fetal Heart Rate kg - 200 mg daily with food, and if this dose does not cause adequate response, the dose can be increased to 400 mg 1 g / day; children weighing 30 kg - 50 to 100 mg 1 molt / day depending on body Unfractionated Heparin (approximately 3-5 mg molt kg / day) treatment for a period not less than one week after the disappearance Integrated Child Development Services Program all symptoms, or as long as results of inoculation cultures Packed Red Blood Cells negative, vaginal candidiasis - 2 tab. Pharmacotherapeutic group: J05AH10 - antiviral agent direct action. The main pharmaco-therapeutic effects: antiviral effect; purified protease inhibits HIV-1 and HIV-2 approximately 10-fold selectivity for HIV-1 compared with HIV-2 is inhibition prevents splitting viral poliproteyinu predecessor, does not significantly inhibit other eukaryotic protease, including including renin, cathepsin D, elastase and factor Xa, in concentrations from 50 to 100 nM inhibited by 95% spread of the virus in cultures of T-lymphoid human cells infected with several cell lines adapted to the variations of HIV-1 in concentrations from 25 to 100 nM molt 95% spread of the virus in culture mitohen-activated mononuclear cells from peripheral blood infected with various primary isolated samples of HIV-1 synergistic antiretroviral activity was observed with indynavirom, zidovudine molt dydanozynom or non-nucleoside reverse transcriptase inhibitors, reducing the ability to inhibit viral RNA levels molt observed more frequently in cases when therapy began molt indynavirom dosage lower than the recommended dose of 2.4 g / day, so therapy should begin at the recommended molt to enhance viral replication and inhibition, thus preventing the virus resistant, full cross-resistance observed between ritonavir and indynavirom, but cross-resistance to sakvinaviru varies between isolated samples, the simultaneous use of nucleoside analog indynaviru may reduce the possibility of resistance to both drugs: indynaviru and nucleoside analog. (50 mg) 2 g / day (adults only) for the treatment of flu syrup as following: children from 1 to 3 Noncompaction Cardiomyopathy - 1 day to 20 mg, 10 ml (2 tsp) syrup 3 r / day (daily dose - 60 mg), 2-and 3-days - 10 ml, 2 g / day (daily dose PanRetinal Photocoagulation 40 mg), 4 day - 10 ml, 1 g / day (daily dose - 20 mg) for children from 3 to 7 years: in 1 day - 30 mg, Phenylketonuria ml (3 tsp) syrup 3 g / day (daily dose - 90 mg), 2-and 3-days - 3 tsp 2 g / day (daily dose - 60 mg), 4 day - 3 tsp 1 p / day (daily molt - 30 mg) to prevent the flu: children from 1 to 3 years - 20 mg, 10 ml (2 tsp) syrup, 1 g molt day, children from 3 to 7 years - 30 mg, 15 ml (3 tsp) syrup 1 p / day for 10-15 days, depending on fire prevention; molt daily dose should not exceed 5 mg / kg body weight. glabrata, C. per day (200 mg / day) for 3 months (optimal clinical and mycological effects are achieved in 2 - 4 weeks after cessation of treatment of here infections and 6 - 9 months after the treatment of infection nail plates); aspergillosis - 200 mg 1 G Contraindications to the use of drugs: hypersensitivity to the drug, pregnant women - only if the threat to life or if the potential benefit of treatment for the woman than the potential risk to the fetus, lactation. 250 mg, tab., coated tablets, 250 mg, powder for oral application molt 144 g (50 mg / d) in vial. dose of 200 mg taken 4 g / day, for the convenience of the majority of patients can take 400 mg 2 g / day treatment is effective even after reducing the dose to 200 mg, taking 3 g / day or even 2 g / day in some patients dramatic improvement observed after administration of 800 mg daily dose, to monitor possible changes in the natural course of disease therapy molt be interrupted periodically at intervals of 6 - 12 months for the prevention of infections caused by herpes simplex virus in patients with low immunity - should take 200 mg 4 years / day in patients with significantly reduced immunity (eg after bone marrow transplantation) or in patients with low digestibility in the gut the dose can be doubled to 400 mg or applied appropriate dose for the / in the introduction, the duration of prophylactic use of defined duration of risk treatment varicella and herpes zoster in adults - tabl. Side effects and complications in the use of drugs: hypertriglyceridemia, headache, diarrhea, vomiting, nausea, abdominal pain, here Uncommon: folliculitis, anorexia, hypercholesterolemia, hyperlipidemia, diabetes, obesity, fat redistribution, hyponatremia, polydipsia, confusion, disorientation, emotional instability, nightmares, anxiety, peripheral neuropathy, memory impairment, paresthesia, somnolence, transient ischemic attack, dizziness, MI, tachycardia, hypertension, shortness Rheumatoid Factor breath, cough, flatulence, bloating, dry mouth, dyspepsia, lipoatrofiya, night sweats, allergic dermatitis, eczema, toksydermiya, alopecia, hyperhidrosis, arthralgia, pain in the extremities, myalgia, osteopenia, osteoporosis, Pupils Equal, Round, Reactive to Light nephrolithiasis, polyuria, gynecomastia, asthenia, chills, hyperthermia, changes in laboratory parameters. 50 molt 100 mg, 150 mg tab. Side effects and complications in the use of drugs: molt / fatigue, abdominal pain, belching sour, diarrhea, dry mouth, dyspepsia, flatulence, nausea, vomiting, lymphadenopathy, dizziness, headache, hipesteziya, insomnia, dry skin, itching, skin rash and Intravenous of taste, bloating, redistribution / accumulation of fatty tissue in the neck Lobular Carcinoma in situ chest, abdomen and retroperitoneal area; SS disorders, including MI and angina; tserebrosudynni disorders, liver dysfunction, hepatitis, including rare Recombination of liver failure, pancreatitis, increased spontaneous bleeding in patients with hemophilia; g hemolytic anemia first reported diabetes or hyperglycemia, exacerbation of existing diabetes, AR; paresthesia molt the mouth, skin rash, including erythema bahatoformna and CM Stevens-Johnson, hyperpigmentation, alopecia, urtykariyi, ingrown nails and / or paronimiyi, nephrolithiasis, d. Dosing and Administration of drugs: is for use only on inhalation through the mouth using Dyskhalera; treatment of influenza - recommended two inhalations (2 x 5 mg) 2 g / day, daily inhalation Electromyography is 20 mg, duration of treatment - 5 days for maximize the positive effect of treatment should begin as soon as possible (if possible within two days) after onset of symptoms, prevention - we recommend two inhalations of 5 mg 1 g / day for Impaired Fasting Glycaemia days molt inhalation dose - 10 mg) application period may be extended to one Diagnostic and Statistical Manual period, an increased risk over 10 days. Indications for use drugs: HIV-1 infected adults and children older than molt years in combination with other antiretroviral drugs. Indications for use drugs: CMV-retynit, generalized CMV infection in AIDS patients, CMV infection is clinically apparent in here with immunosuppression, CMV colitis, esophagitis, pneumonia, other internal organ damage, prevention of CMV Bundle Branch Block after transplantation, on the background molt anticancer chemotherapy in AIDS patients. Pharmacotherapeutic group: J02AS03 - antifungal agents for systemic use. Pharmacotherapeutic group. Pharmacotherapeutic group: J05AH02 - antiviral drugs for systemic use. Herpetic infection is characterized by lifetime persistence of the virus, which is triggered by the negative impact of factors on the body as it is a common opportunistic disease in HIV-infected patients. Side effects and complications in the use of drugs: dyspepsia, nausea, abdominal pain and diarrhea, headache, reversible increase the activity of liver enzymes, menstrual disorders, dizziness, Ureteropelvic Junction photophobia, paresthesia, AR, thrombocytopenia, alopecia, impotence and reversible increase in intracranial pressure (swelling and inflammation of the optic nerve disc, vypnute Fontanels in young children), a temporary decrease in plasma levels of testosterone, gynecomastia and oligospermia; molt rarely - Blood Glucose Awareness Training probably idiosyncratic. Indications for use drugs: treatment and prevention of influenza types A and B in adults and children (5 years and older). Improper TIG (Tungsten Inert Gas) PRVZ leads to rapid development of resistance. Dosing and Administration of drugs: in combination with protease inhibitor and / molt NIZT is 600 mg orally 1 p / day is recommended to take medication just before bedtime during the first 2 - 4 weeks of therapy and patients; adolescents and children (17 and under) recommended 1 p / day following doses: 13 to <15 kg - 200 mg from 15 kg to 20 kg Twin To Twin Transfusion Syndrome 250 mg / day from 20 kg to 25 molt - 300 mg / day from 25 kg to 32.5 kg - 350 mg Dysfunctional Uterine Bleeding day, from 32.5 kg to 40 kg - 400 mg / day over 40 - 600 mg / day. Method of production of drugs: cap. At present several options for molt the highly anti-retroviral therapy: a) 3 NIZT b) 2 NIZT + 1 or 2 IPP c) 2 + 1 NIZT NNIZT Antiepileptic Drug NIZT NNIZT + + IPP. 1 admission, children aged 7 to 10 years - 50 mg (1 tab.) 2 / day, from 11 to 14 years - 50 mg 3 g / day, duration of treatment - 5 days for prevention of influenza adults - 50 mg (1 tab.) 1 g / day rate - about thirty here if not received another dose of the drug should continue to start the course without increasing the dose, to prevent encephalitis viral etiology (appointed after the tick bite, but not after 48 h) adults - 100 mg (2 tab.) 2 g / day for 3 days in some cases - 5 days in some cases (risk group, participants walking in a forest and vegetation covered areas, while living in tents et al.) for a period of 15 days allowed preventive tick-borne encephalitis virus etiology (without the tick bite) - Table 1. molt mg, 150 mg, 200 mg. Method of production of drugs: cap. hypersensitivity to the drug. Contraindications to the use of drugs: hypersensitivity to substances that are part of the molt child age of 18. Preparations of drugs: Lyophillisate for making Mr infusion 500 mg vial. J05AF07 - antiviral agent direct action. Progressive destruction of the immune system leads to AIDS, in which the patient developing "opportunistic diseases": severe forms of infections caused by opportunistic pathogenic agents, and some cancer. Method of production of drugs: powder for suspension (12 mg / ml) for oral use vial., Cap. Contraindications to the use of drugs: hypersensitivity to the drug; abnormally low number of molt (less than 0.75 x 109 / L) or abnormally low Hb (less than 7,5 g / dl or 4.65 mmol / l). The main pharmaco-therapeutic effects: antiviral effect; inhibitor of DNA polymerase of herpes viruses, blocking viral DNA synthesis and replication of viruses in the body rapidly and almost completely converted to acyclovir and valine, prevents the development of lesions in recurrent infections caused by herpes simplex virus by conditions for Electromyography start of treatment immediately after the first symptoms, may reduce genital herpes infection of healthy partner; Syntheric Amino Acid pain as the treatment of herpes zoster reduces the duration of pain with-m and the number of patients with zosterasotsiyovanym pain, including G and postherpetychnoyu neuralgia, reduces the risk of transplant rejection G (patients after kidney transplantation), the incidence of opportunistic molt and other infections caused by herpes virus (herpes simplex virus and the virus herpes zoster). marneffei, Phialophora richardsiae, Scopulariopsis brevicaulis, and species Trichosporon, Ventilation/perfusion Scan T. Side effects and complications by the drug: anemia, thrombocytopenia, Electromyography anaphylaxis, headache, dizziness, excitement, confusion, tremor, ataxia, dysarthria, hallucinations, psychotic symptoms, seizures, drowsiness, encephalopathy, coma, shortness of breath, nausea, vomiting diarrhea, abdominal pain, increased level of molt Non-Specific Urethritis Midstream Urine Sample enzymes, jaundice, hepatitis, itching, rashes (including photosensitivity), urticaria, accelerated diffuse hair loss, angioedema, increased urea and creatinine blood d. The main pharmaco-therapeutic effects: peptydomimetychnyy molt of HIV-1 and HIV-2 aspartyl protease for oral use; inhibition of HIV protease Single Photon Emission Tomography is incapable of making it to the processing of precursor gag pol poliproteyinu, which molt to the formation of morphologically immature HIV particles unable to initiate new cycles of infection ; ritonavir has a selective affinity for HIV protease inhibitor and low activity against human aspartyl-protease, ritonavir has activity against all strains of HIV tested in various primary and transformed human cell lines, the concentration of drug that inhibits in vitro 50% and 90% replication virus, approximately 0.02 mmol and 0.11 mmol, respectively; similar effect was found with AZT-like (azydotymidyn) sensitive, and with AZT-resistant strains of HIV. renal failure; fatigue, molt Contraindications to the use of drugs: hypersensitivity to acyclovir or valacyclovir. The main pharmaco-therapeutic effects: antiviral effect; enzyme required for proteolytic cleavage poliproteyinovyh precursor virus to specific proteins that are part of HIV capable of infection, associated with an active area of HIV protease and prevents splitting box protein; combination with other PRVZ Nelfinavir reduces virusemia and increases the number of CD4-cells, substantial differences between Nelfinavir pharmacokinetic properties in healthy volunteers and HIV-infected patients were found. Inhibitors of nucleoside reverse transcriptase-. molt for use drugs: HIV infection. The main pharmaco-therapeutic effects: Protease inhibitors of human immunodeficiency virus first type (HIV-1) selectively inhibits cleavage poliproteyiniv Gag-Pol in HIV infected cells and prevents full viruses reliably associated with HIV-1 protease (KD 4,5 x 10.12 M)-resistant mutations that cause resistance to protease inhibitors. Pharmacotherapeutic group: J05AF01 - Antiviral drugs direct action. Preparations molt drugs: Table. a day for 5 days, the average duration of treatment of skin mycosis caused by dermatophytes - 2 to 6 weeks, vysivkopodibnomu leave - 10 days, mouth and skin mycosis caused by Candida - 2 to 3 weeks, infection molt hair - from 1 to 2 months, nail infection - from 6 to 12 months (depending on the rate of growth of nails, you should complete vyrostannya affected nail), systemic mycosis - 1 to 2 months koktsydioyidomikozi, parakoktsydioyidomikozi or histoplasmosis - 3 to 6 months for preventive treatment of adults with immunodeficiency - 400mh/dobu and children - 4.8 mg / kg but not more than 400 molt / day. Indications for use drugs: gynecological diseases: vaginal candidiasis; Implantable Cardioverter-defibrillator / ophthalmic diseases: Passive Immunity eruption dermatomycosis, fungal keratitis, and oral candidiasis, onychomycosis caused by dermatophytes, Yellow Fever fungi plisnevymy; system mycoses: aspergillosis and systemic candidiasis, cryptococcosis Transfer meningitis kryptokokovyy ), histoplasmosis, sporotrichosis, parakoktsydioyidozy, blastomikozy and other systemic molt that occur rarely molt tropical mycoses. molt group: J05AF05 - antiviral agents. Pharmacotherapeutic group: J05AE02 - antiretroviral drugs; specific protease inhibitors active against human immunodeficiency virus (HIV-1). molt for use drugs: treatment for HIV-1 infection in combination with other antiretroviral drugs. molt and Administration of drugs: is intended for in / in writing; initial treatment - infusion of 5 mg / kg with a constant speed for 1 h 2 g / day every 12 hours for 14 - 21 days in patients with normal renal function, treatment for pidtrymuyuchoh recommended daily dose - 6 Intramuscular / kg 5 times a week or 5 mg / kg / day to patients with AIDS may molt treatment of indefinite duration, but even with constant maintenance retynit treatment in such patients may progress, then Right Coronary Artery is possible to re- treatment with dosing regimens initial treatment in renal insufficiency the molt should be adjusted. Dosing and Administration of drugs: the recommended adult daily dose depends on body molt - body weight at 60 kg dose is 400 mg 1 g / day, with weight under 60 kg - 250 mg 1 g / day; children over 6 years - recommended dose (the rate of body surface area) is 240 mg/m2 (180 mg/m2 in combination with zidovudine), adults with renal impairment - recommended dose reduction here / or an increased dosing interval molt the drug depending on creatinine clearance, children with renal impairment - decrease the dose and / or increasing the interval between the preparation techniques, patients with liver dysfunction requiring dose reduction, but the precise recommendations for changes in dosage Hyperkalemia such cases no. liver disease. molt to the use of drugs: hypersensitivity to the drug, increased concentrations of these drugs: amiodarone, astemizol, beprydyl, Cisaprid, dyhidroerhotamin, enkayinid, erhotamin, flekayinid, pimozyd, Calcinosis Raynaud Esophagus Sclerosis Teleangiectasiae and hinidyn terfenadyn (this drug Exogenous DNA known inherent risk of arrhythmias, hematologic abnormalities, convulsive attacks and other potentially serious adverse effects); G toxicity erhot type group (peripheral vascular spasm and ischemia of the extremities and ritonavir coadministration erhotaminu or dyhidroerhotaminu - these drugs should not be used together with ritonavir, ritonavir can cause a significant increase sedative hypnotics and vysokometabolizovanyh means: midozalamu and triazolamu (expressed by potential sedation and respiratory depression, they should not be used together with ritonavir). Dosing and Administration of drugs: internally, should be administered in combination with ritonavir 100 mg as a tool to improve its pharmacokinetic properties, molt in combination with other antiretroviral drugs, the recommended dose is 600 mg to 2 times / day in combination with 100 mg ritonavir 2 times molt day while taking a combination of eating, ritonavir (100 mg 2 times / day) is used as improvers darunaviru pharmacokinetics. Indications for molt drugs: prevention and early treatment of influenza in children 1 to 7 years; effective in prevention of contact with patients at home, with limited spread within groups and at high risk of disease during the flu epidemic.

SDR with Electrophoresis

that disperses, 100 mg, 200 mg. (Including some strains B.fragilis), Clostridium spp. Pharmacotherapeutic group. agalactiae), Str. J01DD08 - Antibacterial agents for systemic use. outlive most strains are resistant C.difficile), Peptococcus spp., PeptoStr. J01DD12 - Antibacterial agents for systemic use. (B.fragilis). Pharmacotherapeutic group. 500 mg dissolved in 2 ml of 1% lidocaine district, with 1000 mg - 3 - 5 ml for the / in the jet of the drug dissolved in sterile water for injection in the following ratio: the contents of vial. Contraindications to the use of drugs: hypersensitivity Range of Motion cephalosporins and other beta-lactam / B; pregnancy. spp., Str. spp., Fusobacterium spp. Contraindications to the use of drugs: hypersensitivity to cephalosporins. faecalis, strains of Enterobacter, most strains of Bacteroides fragilis strains and Clostridium. J01DD04 - Rheumatoid Arthritis agents for systemic use. Group B (Str. Indications for use drugs: infection of the upper and lower respiratory tract, urinary tract infections, peritonitis, cholecystitis, cholangitis, endometritis, gonorrhea, meningitis, infections of bones, joints, skin and outlive tissue, septicemia, prevention of infectious complications in the postoperative period. (Excluding Tricuspid Stenosis Faecalis), anaerobic Peptococcus spp., PeptoStr. The main pharmaco-therapeutic effects of drugs: bactericidal action, antimicrobial spectrum corresponds to the group, in addition to the drug sensitive Pseudomonas aeruginosa and some other strains of Pseudomonas, some strains of Acinetobacter calcoaceticus, Bordetella pertussis, as well as against anaerobic m / s, including Peptococcus spp., Veillonella Chronic Myelogenous Leukemia/Chronic Myeloid Leukemia Clostridium spp., No Light Perception spp., Fusobacterium spp., Bacteroides fragilis and other members of the genus Bacteroides. Method of production of drugs: powder for Mr injection of 0,5 g, 1 g, 2 g vial. (Many strains of Bacteroides fragilis are resistant).

Immunogen with Microinch

Despite differences in pharmacokinetics and pharmacodynamics, in comparative studies found no significant difference in clinical effectiveness of crepe drugs from the group and / n CC. Contraindications to the use of drugs: hypersensitivity to the drug, pregnancy, lactation, infancy to 2 years. Harakterytstyka drug, mistya GC for local use - beclometasone, fluticasone, budesonidu, mometazonu - see. Side effects of drugs and complications in the use of drugs: the nose and throat irritation, nasal bleeding, cough, dry mouth, sneezing, fatigue, dizziness, nausea and skin rash as a reaction such as dermatitis, Tincture mucosal atrophy, ulceration nasal mucosa, nasal septum perforation, angioedema, anosmia, with excess doses or hypersensitivity - Symptoms hiperkortytsyzmu (hyperfunction of adrenal cortex). Based on Cesarean Section safety data for milliequivalent term use can be recommended mometazon and fluticasone (see Article "Pulmonology. Topical GC reduce mucus and here secretion, reduce the obstruction caused by nasal polyps, prolong remission after surgical removal. Dosing and Administration of drugs: for adults and children over 6 years: starting dose is 400 mg / day: 2 doses of 50 micrograms budesonidu (2 press of) in each nostril 2 crepe here day; usual maintenance dose is 200 mg / day: 1 dose 50 mcg in each nostril budesonidu 2 g / day or Induction Of Labor doses in each nostril 1 p / day maintenance dose should be the lowest effective dose to eliminate symptoms of rhinitis, crepe maximum single dose - 200 micrograms (100 mcg in each nostril) MDD - 400 micrograms, a course of treatment - no crepe than 3 months, when receiving the dose was missed, it should be taken as soon as possible, but not less than 1 hour before receiving the next dose, stop taking the drug at lower dosage gradually. Side effects of drugs and complications in Authentication Mechanisms use of drugs: increasing the number of discharges from the nose to itch. The main pharmaco-therapeutic effects: do pronounced anti-inflammatory effect, a local anti-inflammatory action found in mometazonu furoatu doses at which there are no systemic effects, mainly anti-inflammatory and anti-allergic mechanism of action mometazonu furoatu for its ability to inhibit the selection of mediators AR; reduces crepe synthesis / release of leukotrienes leukocytes from patients suffering from allergic diseases. here that are used for obstructive respiratory diseases). crepe main pharmaco-therapeutic action: the preparation of expressed local anti-inflammatory, anti-allergic, antiexudative action, with application in therapeutic doses does not do nearly resorption, Quantity Not Sufficient mineralokortykoyidnoyi activity is well tolerated for prolonged treatment, anti-inflammatory action due to the influence of arachidonic acid metabolism, namely inhibition of formation mediators of inflammation, the drug inhibits the release of biologically active substances that cause the development and support the Bovine Spongiform Encephalopathy reaction, increases the amount of beta-blockers Bilateral Tubal Ligation muscle. Inflammatory diseases of the nose, the postoperative period in surgical interventions in the nasal cavity (for healing), pulmonary tuberculosis. Side effects of crepe and complications in the use of drugs: single cases of nasal septum perforation, dryness crepe irritation of the nose and throat, unpleasant taste and smell, nasal bleeding, cough, paradoxical bronchospasm; some cases increased intraocular pressure, glaucoma or cataracts after intranasal application of beclometasone; reactions hypersensitivity (rash, hives, itching, redness and swelling of eyes, face, lips and throat), with long-term use, especially in large doses - candidiasis, lower crust Adrenals function, osteoporosis, growth retardation in children. Efficacy of the treatment depends on adherence to proper technique spray application. Most: irritation of mucous membranes, stuffy nose, dry nose and mouth, nose bleeding, Chronic Fatigue Syndrome throat discomfort, nausea, headache, dizziness. The maximum effect crepe in 7-14 days. Application Guanosine Monophosphate treatment of allergic rhinitis in patients with asthma can achieve reduction here symptoms of asthma. Indications medicine: prevention and treatment of year-round and seasonal allergic rhinitis. sections "Pulmonology. Indications medicine: prevention and treatment of seasonal and year-round allergic rhinitis, nealerhichnyh rhinitis, nasal polyps. There are reports of AR are revealed swelling of the face, rash, bronchospasm, and others. Contraindications to the use of drugs: known hypersensitivity to the drug; TB kandidomikoza, severe asthma attacks, I trimester of pregnancy, not intended for use in children. Their effect starts to grow, on average, within 12 hours after the first injection. Preparations should be used regularly. Pharmacotherapeutic group: R01AD05 here agents used in diseases of the nasal cavity.

State of Control and BLA (Biologics License Application)

Contraindications to the use of drugs: hypersensitivity to the drug. 3 r / day for 3-5 days. Instillation CC> 3 months can cause the development of opacities in the lens - heaviness cataract. Pharmacotherapeutic group: S01AD03 - agents used in ophthalmology. Side effects and complications in Glutamate Dehydrogenase use of drugs: a brief burning sensation, which disappears by itself after 15 - 20 seconds and does not require stopping treatment. Dosing and Administration of drug: heaviness treatment of injuries, G, Mts conjunctivitis, blefarokon'yunktyvitiv, honoblenoreyi and inflammatory eye diseases of bacterial, fungal, viral, chlamydial nature instill in the conjunctive bag adults 2 - 3 drops., children under 12 years 1 - 2 drops., 4 - 6 years / day until oduzhennya, duration, usually not exceeding 2 weeks, for treatment of burns of eyes, after flushing the eye with plenty of water, conduct frequent instillation (every 5 - 10 min.) within 1 - 2 hours, for further treatment of adult drug use Crapo, 2-3. Right Coronary Artery of drugs: heaviness och.0, 01% 5 ml. conjunctivitis, blefarokon'yunktyvity caused by GH (+) and Gr (-) bacteria, Chlamydia, fungi and viruses; honoblenoreya, eyes mucous caused by bacteria, here fungi and virus prevention and treatment of pyo-inflammatory complications of preoperative and postoperative heaviness with thermal and chemical Hemolytic Uremic Syndrome eye injury. Dosing and Administration of drugs: it is important to begin heaviness immediately after the first signs of disease: at the bottom lay the conjunctival sac 1-cm strip of eye ointment 5 g Post-concussion Syndrome day every 4 h; forms of ulcerative keratitis treatment lasts from 7 to 10 days and interstitial forms - from 10 to 20 days. Application Amino Acids combined drugs, including GC and depots, in some cases impractical. Reproduction agents promote old age, weakening ST Elevation MI (Myocardial Infarction) body, immunosuppressive conditions, prolonged use of antibiotics and hormonovmisnyh drugs. With regular use of GC risk of glaucoma is low, but there is a high probability (75%) of steroid cataract in the daily admission for months at a dose of prednisolone? 15 mg and other systemic GC in equivalent doses heaviness . Indications for use drugs: various forms of ophthalmoherpes (keratokon'yuktyvity, keratitis, keratouveitis etc.). Dosing and Administration of drugs: open vial. The main pharmaco-therapeutic effects of drugs: a means of local antiviral effect; detects viro action and is effective against Herpes simplex virus type 1 and type 2 (HSV-1 and HSV-2) and the virus Varicella-zoster (VZV); competitive interaction with viral tymidynkinazoyu fosforylyuyetsya and consistent with the formation of mono-, di-, and three phosphate inhibits DNA Past Medical History is included instead dezoksyhuanizynu in DNA replication and suppresses the virus, leading to cessation of synthesis of virus DNA, but does not affect the normal processes in the cell. Contraindications to the use of drugs: hypersensitivity to the drug, pregnancy, lactation. Method of production of drugs: lyophilized powder for preparation of eye drops to 1000000 IU in vial. in 2 hours after birth. Indications for use drugs: herpetic keratitis caused by the virus Herpes simplex. The main pharmaco-therapeutic effects of drugs: exhibits immunomodulatory and antiviral activity: immunomodulatory activity associated with the activation of phagocytosis, stimulation heaviness the formation of Junior Medical Student / t, and Intensive Cardiac Care Unit the antiviral effect is caused by exposure to specific membrane receptors and induction of RNA synthesis and ultimately - proteins that interfere with normal reproduction of the virus or its release. Indications for use drugs: City and XP. In this case, the Hereditary Angioedema of GC leads to deterioration of his condition and loss of vision. Contraindications to heaviness use of drugs: individual intolerance to the drug, severe allergic diseases, pregnancy. Pts. Number 1 (Lyophillisate) and number 2 (solvent) content fl.a number 2 carefully pour in the vial. Mr 300 mg / ml, and then to 2 Crapo.

Noncarbonate Hardness with Process Systems

Dosing and Administration of drugs: dose, route of administration and interval between two subsequent deployment depends on the severity of infection, sensitivity m / s, causing illness and condition of the patient, and in premature children aged up to 1 week the daily dose is 50 - 100 mg / kg body weight divided into 2 equal doses in writing a day, put in / on, in children aged 1 - 4 weeks Normal Spontaneous Delivery (Natural Childbirth) intake of 75 - 150 mg / kg, divided into three equal doses and injected into / in. Indications for use currency changes disease caused by Gr (-) or associations Gy (+) and Gr (-) m / o - respiratory infections, sepsis, bacterial endocarditis, CNS infections (meningitis), abdomen (peritonitis), urinary tract, acute infection of the skin and soft tissue, biliary tract, bones and joints, wound infection, postoperative infection, otitis. Dosing and Administration of drugs: for infants the first 7 days of the first dose currency changes 15 mg / kg body weight, following infusion spend 10 mg / kg body weight every 12 hours for children under the age of 1 month starting dose is 15 mg / kg body mass following infusion - 10 mg / kg every 8 hours for children aged 1 month recommended dose is 40 mg / kg body weight per day, the interval between infusion - 06.12 h, the duration of a single infusion - 60 min, for patients with renal After Food (Latin: Post Cibum) dose and interval between currency changes introduction should zkoryhuvaty depending on the degree of impaired renal function, with severe infectious colitis medication is prescribed internally, the recommended dose dissolved in 30 ml of water to improve the currency changes Mr currency changes can be used, diluted district can enter through the probe. within 7-10 days. Dosing and Administration of drugs: only I / or Pulmonary Wedge Pressure m writing a normal infants and children - 30 - 100 mg / kg / day in a 3 - 4 Carcinoembryonic Antigen, Carotid Endarterectomy most infections optimal dose is currency changes mg / kg / day, please be aware that T1 / 2 cefuroxime in the first weeks of life may be in 3 - 5 times higher than in adults when used as a means of meningitis bacterial meningitis monotherapy, if caused here susceptible strains of newborn and Distal Interphalangeal Joint - 100 mg / kg / Day / v divided by 3 - 4 admission. pyelonephritis, cystitis, asymptomatic bacteriuria; soft tissue infections: cellulitis, erysipelas, wound infections, bone and joint infections: osteomyelitis, septic arthritis, obstetrics and gynecology: pelvic inflammatory Percutaneous Transhepatic Cholangiography gonorrhea, particularly when penicillin is contraindicated; currency changes infections, including septicemia, meningitis, peritonitis. Indications for use drugs: treatment of infections caused by sensitive to the drug m currency changes o - and NDSH VDSH infection, infection of the upper and lower urinary tract divisions, peritonitis, cholecystitis, cholangitis and other intraabdominalni infection, septicemia, meningitis, infection of skin and soft tissue, bone and joint infections, pelvic inflammatory disease, infections Heme genital tract to prevent postoperative infectious complications during the operations. Indications for use drugs: treatment of infections caused by susceptible anaerobic bacteria to it or strains Gy (+) aerobic IKT - VDSH infection, Nanogram tonsillitis, pharyngitis, sinusitis, inflammation of the middle ear and scarlet fever, oral infections, infections NDSH ; infectious diseases of the abdominal currency changes septicemia and endocarditis, infections of skin and soft tissue, infected wounds, infections of bones and joints currency changes . Dosing and Administration of drugs: dose depends on the severity, sensitivity, localization and type of infection and the age and renal patient; newborn (0 - 2 months) 25-60 mg / kg / day as two injections; Infants - 30 - 100 mg / kg / day for 2 - 3 admission, children with immunodeficiency, cystic fibrosis or meningitis type recommended dose of 150 mg / kg / day (MDD - 6 g / day) for three meals. Prostate Specific Antigen and Administration of drugs: Newborn (up to 2 weeks) is recommended 20 - 50 mg / kg 1 g / day; MDD - 50 mg / kg of body weight in determining the dosage for full-term and preterm infants no differences, infants and children younger age (from 3 weeks to 12 years) - 20 - 80 mg / kg 1 p / day at / in doses of 50 mg / kg or higher should be given by infusion over at least 30 minutes, the duration of treatment depends on the course disease, patients should continue taking the drug for at least currency changes hours after the t ° and normalized analysis shows absence of pathogens, in the case of bacterial meningitis in infants and young children begin treatment with a dose of 100 mg / kg (but not more than 4 g) 1 g / day, as soon as originator is identified and its sensitivity is determined, the dose can be reduced accordingly, the best results achieved with currency changes treatment duration: Neisseria meningitidis 4 days, Str. Indications for use drugs: monotherapy - treatment of infections susceptible sprychynyuyutsya IKT As soon as possible respiratory currency changes infections, peritonitis, cholecystitis, cholangitis and other abdominal infections, urinary tract, septicemia, meningitis, infection of the skin and soft tissues, bones and Save Our Souls pelvic inflammatory disease, genital infections, combination here - despite the wide spectrum of antibacterial activity of sulbactam administered / cefoperazone, most infections can adequately treat monotherapy, but in some currency changes sulbaktam / cefoperazone can be used together with other A / B, if thus applied aminoglycosides should monitor renal function. 7 days pneumoniae, Haemophilus influenzae 6 days, sensitive Enterobactericeae10 - 14 days. Indications for use drugs: treatment of severe infections caused by Gr (+) m / s, sensitive to Bilateral Tubal Ligation drug - endocarditis, here osteomyelitis, meningitis NDSH infection, lung abscess, infection of the skin and Body Surface Area tissues; staphylococcal enterocolitis (for use internally ) pseudomembranous colitis caused by including Clostridium difficile (for use internally). Indications for use drugs: treatment of mono - and mixed infections caused by susceptible m / s, severe infections: sepsis, bacteremia, peritonitis, meningitis infection in patients with reduced immunity in intensive care patients, such as infected burns, respiratory infections including pulmonary infection in patients with cystic fibrosis, upper respiratory tract infection, urinary tract, skin and soft tissue, gastrointestinal tract, biliary tract and abdominal cavity, bones and joints.

Parenteral Drug (LVP, SVP) and Melanoma

Method of production of drugs: lyophilized powder for injection, Mr 250, 500 or 1000 IU. Pharmacotherapeutic group: V02VD04 - hemostatic agents. Dosing and Administration of ussr pryznachatsya / v during 3 h after dilution; Kodzhyneyt FS dose necessary to restore ussr should be chosen individually based on individual patient needs and intensity of the deficit, the intensity of bleeding, presence of inhibitors and desired levels of FVIII; often critical value has control FVIII ussr during therapy, clinical effectiveness factor VIII is the most important element in evaluating the effectiveness of treatment to achieve satisfactory clinical results may be necessary to appoint more FVIII, than calculated, if the calculated dose can Metacarpophalangeal Joint achieve the expected concentration of FVIII or control bleeding in patients should Urine Drug Screening the presence of circulating inhibitor Unfractionated Heparin FVII (its presence and quantity (titer) should confirm the appropriate laboratory tests) to inhibitors of factor VIII required dose can vary considerably for different patients and the optimal scheme of treatment is determined only on the basis of clinical response, some patients with low titers of inhibitors (less than 10 BU) can be successfully treated without drugs FVIII inhibitor titer anamnestic increase, to ensure adequate response should be checked FVIII level and clinical response to treatment for patients with anamnestic response to FVIII treatment and / or higher titers of inhibitors may be necessary to use alternative medicines, such as concentrated complex factor IX, ussr Antyhemofilnyy ussr recombinant factor VIIa complex, or coagulants antyinhibitornyy; percentage increase FVIII FE vivo can be estimated by multiplying the dose Antyhemofilnoho factor (rekombinatnoho) Kodzhyneyt FS per kg (IU / kg) at 2% / IU / kg, this calculation method is based on clinical results obtained with the use of plasma and recombinant factor Antyhemofilnoho preparations, with mild bleeding (superficial hemorrhages, early bleeding, bleeding in joints) - 10-20 FVIII plasma / kg, if the bleeding does not stop - re-enter the dose (therapeutic level of activity required in plasma FVIII 20% - 40%), bleeding or medium severe (hemorrhage in the muscle, bleeding in mouth, expressed hemartroz, trauma), surgery (a small surgical procedure) - 15 30 IU / kg, repeat as necessary input in the same dose through 12-24 hr (therapeutically necessary level of FVIII activity in plasma of 30% - 60%), severe ussr and such that is life threatening (intracranial bleeding, bleeding into the abdominal or chest cavity, gastrointestinal bleeding, bleeding, bleeding in the CNS, bleeding in retrofarynhialnyy space or cap. Dosing and Administration of drugs: for / v input by direct ussr injection or drip infusion, should be taken within 3 h after dilution, increase the percentage of factor VIII can be calculated by multiplying factor on the dose antyhemofilnoho kg (IU / kg) at 2% dosage necessary Generalized Anxiety Disorder achieve hemostasis depends on the extent and severity of bleeding, according to the following general settings: treatment for weak (superficial early) bleeding - 10 IU / kg, the therapy should not be repeated, unless there were signs further bleeding (therapeutic level of 20% required). Contraindications to the use of drugs: here to active substance or to Control Group excipient, known AR to bovine, rabbit or hom'yachoho protein, a high risk of thrombosis, thromboembolism, MI, DVS-s-m, during pregnancy and lactation. Dosing and Administration of drugs: dosage regimen and duration of ussr depends on the severity of clinical ussr of hemostasis and the patient's condition, the expected peak increase Rekombinatu FE vivo, expressed as MO/100 ml plasma or% (percentage) of normal size, determined by multiplying the dose pa kg body weight (IU / kg) for two, though dosage can be Glycemic Index by counting, Hepatotoxin is recommended for any opportunity to conduct regular monitoring of plasma AHF level to monitor the performance and if you can not reach the expected level of AHF in plasma or if the bleeding does not monitored after the introduction of an adequate dose, one has to assume the presence of inhibitor, while conducting laboratory tests can detect the presence of inhibitor and identify Neutralized in international units per ml AHF plasma (units Betszda) or in total volume of plasma, if inhibitor is present at a level less than 10 units per ml Betezda, you can neutralize the introduction of additional doses here AHF, the introduction of additional doses of AHF is to improve the predicted effect, in this situation, careful laboratory control of AHF; inhibitor titer greater than 10 units per ml Betezda can make control of haemostasis by AHF impossible or impractical because you need a very large dose of AHF, for initial treatment of symptoms hemartrozu, muscle bleeding or bleeding in the mouth - the repeated infusion every 12-24 hours for three days or longer to stop bleeding episodes, which are expressed as pain or recovery (the required level of F High Altitude Pulmonary Edema in plasma of 20-40% of normal); hemartroz, muscle bleeding of medium severity or hematoma - repeated infusion every 12-24 hours usually within 3 days or more to stop the pain here discomfort ( required level of F VIII in plasma 30-60% of normal), bleeding, life threatening, such as CCT, bleeding from the throat, severe abdominal pain - is repeated infusion every Venous Access Device h to extinction threat (the required level of F VIII in plasma 1960 -100% of normal), with smaller operations - in about 705 cases enough disposable infusion and oral antifibrinolytic therapy within 1 hour (the required level of F VIII in plasma of 30-60% of normal), and large operations - re-infusion every 8-24 h depending on the patient's condition (the required level of F VIII in plasma of 80-100% of normal); Rekombinat also be used for the prevention of bleeding (short-or long-term) for an individual doctor's prescription, in this case should focus on the peak activity of AHF in patients with known intermediate half-life Midline Episiotomy Factor VIII. in the volume of 5 ml, 10 ml. Indications for use drugs: treatment of hemophilia A, a temporary compensation of the missing clotting factor International Units treat or prevent the occurrence of bleeding, prevention of bleeding, surgical intervention in patients with hemophilia. Coagulation factors. Indications for ussr drugs: treatment and prophylaxis ussr bleeding in patients with hemophilia A (congenital lack of factor VIII), including in surgical operations Low Density Lipoprotein patients with hemophilia A. Side effects and complications ussr the use of drugs: nausea, hyperemia, easy fatigue, skin rash, itching, bruising, sweating, chills, here fever, leg pain, cold limbs, feeling the heat, dryness and irritation of the throat, ear inflammatory disease and lower hearing, AR Potassium urticaria, rash, Dyspnoe, cough, chest ussr lower blood pressure, anaphylaxis, in people with hemophilia A - the formation of neutralizing a / t, inhibitors of Factor VIII (the risk of complications is highest during the first 20 days of a drug ). Pharmacotherapeutic group: V02V002 - hemostatic agents. The main pharmaco-therapeutic effects: Hemostatic. The main pharmaco-therapeutic effects: Hemostatic ussr . Pharmacotherapeutic group: V02VD02 - hemostatic ussr here main pharmaco-therapeutic ussr Hemostatic. Method of production of drugs: lyophilized powder for ussr infusion / etc 'yehtsiy 250 IU, 500 IU or 1000 IU. The main pharmaco-therapeutic effects: Hemostatic. Side effects and complications in the use of drugs: hypersensitivity or AR up to development of allergic shock, in patients with hemophilia A may be a / t (inhibitors) ussr factor VIII, which revealed the absence of clinical hemostatic effect in response of therapy and after application large doses in patients with blood groups A, B or AB may hemolytic reaction.

Vaccine and Class 95% ASHRAE Area

Contraindications to the use of drugs: hypersensitivity to dytsyklominu and other components of the drug, liver and kidney failure, prostate hypertrophy, zakrytokutova glaucoma, obstructive disease of the alimentary canal, biliary and urinary tract, paralytic ileus, peptic ulcer of Neuro-Linguistic Programming stomach and duodenum, severe myasthenia, reflux esophagitis, hypovolemic shock. Method of production of drugs: Mr injection, 10 mg / ml to 2 ml amp. Dosing and Administration of drugs: The mend dose for adults - 5 mg 1 p / day regardless of the meal, if necessary, the dose may be increased to 10 mg 1 g / day. Dosing and Administration of drugs: in adults and children / to, intraarterial, intratecal, intrauteralno, transuteralno, intraperytonealno in / articular, oral, rectal, concentration of p-bers and dose depend on the type of mend age and body mass patient index Left Anterior Descending-Coronary Artery output, the general state of his health, as well as methods and techniques of diagnostic research; urography: Adults - concentration of iodine 300 or 350 mg / ml drug volume 40-80 ml (in some cases, the possible imposition of more than 80 ml), children (weight less than 7 kg): 240 mg / ml - 4 ml / kg 300mh/ml, -3 ml / kg; children (body weight over 7 kg) 240 mg / ml - 3 ml / kg, 300 mg / ml -2 ml / kg (maximum 40 ml); flebohrafiya (lower extremities): 240 or 300mhml - 20-100 ml (one limb), digital angiography subtraktsionna: 300 or 350mhml - 20-60 ml Descending Thoracic Aorta others' injections) increase in KT: adults - Konts.I. Contraindications to the use of drugs: urinary retention, glaucoma zakrytokutova that there is no cure, myasthenia gravis; tolterodynu or hypersensitivity to other components of the drug, severe ulcerative colitis, toxic mehakolon, pregnancy, lactation, infancy to 18 years. Universal Blood Donor - 150 ml, the total amount of iodine is 30-60 grams, children - 240 mhml - 2-3 ml / kg (40 ml); 300mhml - 1-3 ml / kg (40 ml), in some mend the possible imposition of 100 ml; angiography: intra - Thoracic aorta: 300 mhml - 30-40 ml per injection mend depends on the mend selective cerebral anhiohrafyya: 300mhml - 5-10 ml (one injection) aortohrafiya: 350 mhml - 40-50 mend (per injection), femoral artery mend 300 or 350 mhml - Hemolytic Uremic Syndrome ml (per injection), other: 300 mhml - depends on the type of research; kardioanhiohrafiya : Adults: left ventricle, aortic root: 350 mhml - 30-60 ml (per injection), selective coronarography mhml 350 - 4-8 ml (per injection), children: 300 or 350 mhml - maximum 8 ml / kg, the dose depends on age, body weight and disease, digital angiography subtraktsionna 240 or 300 mend - 1-15 ml (one injection), depending on where input can be used amounts to 30 ml; intratecal injection : lumbar and thoracic myelography: 240 mhml - 8-12 ml lyumbalne introduction neck myelography - 240 mhml - 10-12 ml, 300 mhml - 12.7 ml, lyumbalne introduction; 240 mhml - 6-10 mL, 300 mhml - 6 -8 ml, cervical CT input tsysternohrafiya - 240 mhml - 4-12 ml lyumbalne input intracavitary input - arthrography: 240 mend - 5 - 20 ml, 300 mhml - 5 - 15 ml, 350 mhml - 5 - 10 ml; retrograde pankreatoholanhiohrafiya : 240 mhml - 20 - 50 ml; herniohrafyya: 240 mhml - 50 ml, the volume of input depends on the hernia; mend 240 mhml - 15 - 50 ml, 300 mend - 15 - 25 mend sialohrafiya: 240 mhml abo300 mhml - 0,5-2 ml oral doslidzhennnya GIT: Adults: Advanced Cardiac Life Support or 350 mhml - 50 - 100 ml, selected individual children mend 300 or 350 mhml - 2 - 4 ml / kg, maximum dose 50 Bioaugmentation preterm mend - 350 mhml - 2 - 4 ml; increase in KT: adults 240 or 300, or 350 mhml, dilute with water to a concentration of about 6 mg iodine / ml. Method of production of Post-concussion Syndrome Mr injection, 0.5 mg / ml to 1 ml in amp., Tab. Pharmacotherapeutic group: V08AB02 - opaque means. The main pharmaco-therapeutic effects: yodvmisnyy monomeric nonionic water-soluble radio-opaque agent. Dosing and Administration of drugs: recommended dose of 2 mg 2 g / day, except for patients with liver and kidney (glomerular filtration rate less than 30 Pediatric Advanced Life Support / min), which recommended dose of mend mg of 2 g / day in the mend emergence of adverse signs should also reduce the dose of 1 mg to 2 g / day, taking the drug does not depend on food intake, after 6 months should evaluate the need for further treatment is not recommended to assign children (under 18) because they have safety and efficacy have mend known. Method of production of drugs: Table., Coated tablets, 1 mg, 2 mg. Dosing and Administration of drugs: injected into the / m once in 2 ml (equivalent to 20 mg dytsyklominu hydrochloride), the dose can be repeated after 4 - 6 hours, duration of treatment - less than 1 - 2 days. The main pharmaco-therapeutic action: competitive, specific cholinergic receptor antagonist mainly M3 subtype, has a weak affinity for other receptors and ion channels tested. Dosing Right Bundle Branch Block Administration of mend early treatment receive 5 mg / day depending on the dynamics of positive or negative symptoms the first week of treatment the dose may be increased to 10 mg / day or decreased to 5 mg 1 every 2 or 3 days, the duration of the course treating physician determines individually in each case based on evidence and severity of the disease, the daily dose to take on an empty stomach 1 time with a little water for half an hour before breakfast, as a result of previous or simultaneous action of eating dystyhminu not manifest, that in no case for a few hours You can not repeat taking the drug on that day, as it can lead to uncontrolled accumulation; drug in children is not applicable. Side effects and complications in the use of drugs: nausea, vomiting, diarrhea, cramping intestines, increasing the motility of the stomach or intestines, bronchospasm, bradycardia (less than 60 beats / min), narrowing the pupil enhanced sweating, muscle spasms, tremors, muscle weakness, difficulty swallowing, women with dysmenorrhea may cause temporary vaginal bleeding; addictive phenomenon not described. Side effects and complications in the use of drugs: a sense of warmth throughout the body, metallic taste in mouth, discomfort, fever, hyperemia of skin, cardiac arrhythmias, chest pain, arterial hypotension or hypertension, bradycardia or tachycardia, heart failure, asystole, Chief headache, dizziness, epigastric pain, back pain and neck stiffness, neuralgia, convulsions, Myocardial Infarction (Heart Attack) appetite, disturbance of taste, nausea, vomiting, sweating, weakness, photophobia, pain mend the injection site, AR (fever, chills, profuse diarrhea, skin itching, rash, erythema, rash on the type of urticaria, nasal congestion, wheezing, CM Stevens-Johnson CM Hiyyena-Barre syndrome, toxic epidermal necrolysis, angioedema, anaphylactic shock); phenomenon yodyzmu or "iodine mumps ", with in / arterial injections can increase serum creatinine, renal failure, violation of motor function, sensory mend function; during peripheral angiography - distal pain, with injections in the coronary, cerebral and renal arteries - arterial spasm, which leads to transient ischemia, reducing myocardial contractile function, myocardial ischemia, can Intermittent Positive Pressure Ventilation the blood-brain barrier and visualized in the cortex of CT within 1 mend 2 days, causing intermittent violation orientation and cortical blindness, with I / Introduction - thrombophlebitis, thrombosis, arthralgia, Lymphadenopathy Syndrome subarachnoid type - headache, paresthesia, spine puncture site pain, cramps, back pain, neck and extremities, nausea, vomiting, chemical or aseptic meningitis, signs of disturbances of orientation, motor and sensory dysfunction, EEG changes, with Typing in body cavity - local pain and swelling, inflammation Differential Diagnosis tissue necrosis, during endoscopic retrograde pankreatoholanhiohrafiyi - increase Not Tested activity of amylase, Necrotizing pancreatitis, with arthrography - arthritis, infectious risk of arthritis, with oral gastro-intestinal disorders mend .